Navigation Links
Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
Date:3/13/2008

WALTHAM, Mass., March 13 /PRNewswire/ -- Proteon Therapeutics, Inc. (http://www.proteontherapeutics.com), a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, has appointed Gregory D. Phelps, a seasoned biopharmaceutical executive, to the Company's Board of Directors. Mr. Phelps brings more than 30 years of executive leadership and experience in the medical products and biotechnology industries to Proteon.

"Greg's extensive experience in leading both large and small biotechnology companies through financing and licensing transactions as well as biologic product development, approval and launch makes Greg an ideal fit for our Board," said Timothy Noyes, Proteon's president and CEO. "We are extremely fortunate to have attracted someone with Greg's business skills and acumen to the Proteon Board of Directors."

"I am very pleased to join Proteon's Board of Directors given the significant potential for important medical advances based on the Company's technology and the strength of the management team and investor group," said Greg Phelps. "I personally look forward to working closely with the Company as it pursues its business and product development opportunities."

Gregory D. Phelps' career has been focused for over thirty years in the medical products and biotechnology fields, where he has held Chief Executive Officer and other executive management positions in several companies. He has served as Chief Executive Officer of RenaMed Biologics, Inc., Ardais Corporation, Viagene, Inc. and ZymoGenetics, Inc. He has also served as Vice Chairman of Dyax Corporation, Executive Vice President of Genzyme Corporation and Vice President of Baxter Travenol Laboratories, Inc (now Baxter Healthcare). Mr. Phelps is currently on the Board of Directors of EPIX Pharmaceuticals and has previously served on the Boards of Directors of nine public and private companies in the health care field, as well as on the Boards of The Hemophilia Foundation of California and the Charles River School of Dover, MA. He holds a B.S. in Electrical Engineering from Bradley University and an MBA from Harvard Business School.

About Proteon Therapeutics

Proteon Therapeutics, Inc., is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical, rapidly expanding medical needs of patients with kidney and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary pharmaceuticals. The company is headquartered in Waltham, MA, and has research facilities in Kansas City, MO. For additional information please visit http://www.proteontherapeutics.com.


'/>"/>
SOURCE Proteon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
2. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
3. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
4. Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
5. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
6. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
7. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
8. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
9. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
10. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
11. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now offering ... 50 million stem cells total, patients may choose which extremities they would like treated. ... joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from ...
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management ... reasons it did not take off as quickly as people initially expected, and where ... towards capturing data electronically for clinical trials and then repurposing it for downstream analysis, ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver this new technology ... technology of its kind on the market and we were pleased that the IFT ... of traditional cultured ingredients, creating a natural way to extend the shelf life and ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... is commonly used to suppress pigment formation in zebrafish embryos, maintaining optical transparency ... led by Dr MA has been using the zebrafish model to investigate the ...
Breaking Biology Technology:
(Date:7/4/2020)... ... July 03, 2020 , ... Aesthetics Biomedical (ABM), a ... awards for not only the products and treatments developed, but also the dedicated ... RF. All the brands built by ABM have received several honors already for ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... R&D, today announced that it has entered into a multi-year contract with ... to support their translational and clinical research strategy to discover and develop ...
(Date:6/23/2020)... ... June 22, 2020 , ... The field of quantitation of ... assays (LBA) have dominated this area. However, the use of mass spectrometry in this ... now necessitates the question “How do you choose which approach to use (LBA or ...
Breaking Biology News(10 mins):